Gall Bladder Cancer
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
- Details
ClinicalTrials.gov ID:
NCT03773302
Diagnosis Type:
NA
USOR Number:
- Address
3410 Worth Street, Suite 400
Dallas, TX 75246
P: (214) 370-1300